COPD and glycopyrronium responsiveness assessment: An appraisal
Clinical Trial Registration: ECR/159/Inst/WB/2013/RR-20 Background: Glycopyrronium bromide (a long-acting antimuscarinic agent: LAMA) appears pharmacokinetically suitable for testing bronchodilator responsiveness as salbutamol (short-acting β2-agonist: SABA). Exploring the feasibility, acceptability, degree of reversibility with glycopyrronium, and its comparison with that of salbutamol may be intriguing. Methods: New, consecutive, and willing outpatient attendees in the same season of the two consecutive years with chronic obstructive pulmonary disease (FEV1/FVC <0.07; FEV1 <80% of pred... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Reihe/Periodikum: | Lung India, Vol 40, Iss 3, Pp 227-234 (2023) |
Verlag/Hrsg.: |
Wolters Kluwer Medknow Publications
|
Schlagwörter: | antimuscarinic agents / bronchodilator reversibility / fev1 / glycopyrronium / lama / saba / salbutamol / Diseases of the respiratory system / RC705-779 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27248953 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.4103/lungindia.lungindia_376_22 |